Skip to main content

Advertisement

SpringerLink
Log in

Tamoxifen-induced fatty liver disease in a Caucasian patient

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Saito K, Goda K, Kobayashi A, Yamada N, Maekawa K, Saito Y, Sugai S (2017) Arachidonic acid-containing phosphatidylcholine characterized by consolidated plasma and liver lipidomics as an early onset marker for tamoxifen-induced hepatic phospholipidosis. J Appl Toxicol 37:943–953

    Article  PubMed  CAS  Google Scholar 

  2. Lin Y, Liu J, Zhang X, Li L, Hu R, Liu J, Deng Y, Chen D, Zhao Y, Sun S et al (2014) A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer. Cancer Sci 105:1182–1188

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Erasmus Medical Center, Rotterdam, The Netherlands

    Karel Eechoute, Ron H. J. Mathijssen & Teun van Gelder

Authors
  1. Karel Eechoute
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ron H. J. Mathijssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teun van Gelder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karel Eechoute.

Ethics declarations

Conflict of interest

Karel Eechoute declares that he has no conflict of interest. Ron Mathijssen declares that he has no conflict of interest. Teun van Gelder declares that he has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eechoute, K., Mathijssen, R.H.J. & van Gelder, T. Tamoxifen-induced fatty liver disease in a Caucasian patient. Breast Cancer Res Treat 171, 243–244 (2018). https://doi.org/10.1007/s10549-018-4817-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-018-4817-8

Search

Navigation